We are delighted to present the groundbreaking research paper titled "Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects" authored by Georg Ferber, PhD, Dilshat Djumanov, PhD, Ulrike Lorch, MD, FFPM, Edward Jackson, BSc, MSc, PhD, MBChB, Joao Almeida Melo, James Rickard, MPharm, and Jorg Taubel, MD, FFPM, FESC.
A collaboration between renowned institutions such as Statistik Georg Ferber GmbH, Richmond Pharmacology Ltd, King's College London, and St George's University of London, this multidisciplinary team has delved into the intricate relationship between meals and the electrical activity of the heart, as reflected by the QT interval on an electrocardiogram (ECG).
Through a comprehensive meta-analysis of nine studies, the authors reveal the consistently measured interplay between meal composition, timing, and QTcF alterations, offering a valuable contribution to the refinement of cardiac safety assessment in drug development practices. These insights giving rise to the possibility of using effect of a meal to remove the need for a challenge drug (often Moxifloxacin) having to be given, to negatively alter the rhythm of the heart, in parallel reducing antibiotic consumption.
This research not only advances our understanding of meal-induced QTcF changes but also holds promise for more efficient, less harmful and patient-focused drug development, contributing at the same time to the global effort against antimicrobial resistance (AMR).
You can download the full paper here
RRI Lead Specialty Research Physician wins award for Cardiovascular risk factor analysis of data associated with UK grocery brand Tescos
We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.
Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).
12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.
Here we report our recent work on the cardiac safety of nolasiban.
Findings from our recent study show how cardiac ion channel blocking agents could increase the risk of sudden cardiac death in patients with type 1 diabetes, particularly in women.
.svg)
